File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Endomyocardial Implantation of Autologous Bone Marrow Mononuclear Cells in Advanced Ischemic Heart Failure: a Randomized Placebo-Controlled Trial (END-HF).

TitleEndomyocardial Implantation of Autologous Bone Marrow Mononuclear Cells in Advanced Ischemic Heart Failure: a Randomized Placebo-Controlled Trial (END-HF).
Authors
Issue Date2014
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/medicine/cardiology/journal/12265
Citation
Journal of Cardiovascular Translational Research, 2014, v. 7 n. 6, p. 545-552 How to Cite?
AbstractPrior studies suggest that endomyocardial implantation of autologous bone marrow (BM) mononuclear cell therapy improves symptoms and left ventricular (LV) function in patients with refractory angina; however, the therapeutic efficacy in patients with ischemic cardiomyopathy is unclear. In a randomized, double-blind, placebo-controlled trial, 28 patients with advanced ischemic cardiomyopathy [New York Heart Association III-IV, LV ejection fraction (LVEF) <40 %] were assigned in 2:1 ratio to receive endomyocardial injection of BM cells (100 million, n=19) or placebo (n=9), guided by electroanatomical mapping. After 6 months, there was no significant difference between the two groups in LV ejection fraction (LVEF) and LV end-systolic volume (LVESV), LV infarct volume, and LV peri-infarct ischemic volume as determined by cardiac magnetic resonance imaging or exercise capacity. In conclusion, endomyocardial implantation of autologous BM mononuclear cells did not improve LV function or remodeling in patients with advanced ischemic cardiomyopathy. © 2014 Springer Science+Business Media.
Persistent Identifierhttp://hdl.handle.net/10722/203107
ISSN
2015 Impact Factor: 3.197
2015 SCImago Journal Rankings: 1.567
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorSantoso, T-
dc.contributor.authorSiu, DCW-
dc.contributor.authorIrawan, C-
dc.contributor.authorChan, WS-
dc.contributor.authorAlwi, I-
dc.contributor.authorYiu, KH-
dc.contributor.authorAziz, A-
dc.contributor.authorKwong, YL-
dc.contributor.authorTse, HF-
dc.date.accessioned2014-09-19T11:30:49Z-
dc.date.available2014-09-19T11:30:49Z-
dc.date.issued2014-
dc.identifier.citationJournal of Cardiovascular Translational Research, 2014, v. 7 n. 6, p. 545-552-
dc.identifier.issn1937-5387-
dc.identifier.urihttp://hdl.handle.net/10722/203107-
dc.description.abstractPrior studies suggest that endomyocardial implantation of autologous bone marrow (BM) mononuclear cell therapy improves symptoms and left ventricular (LV) function in patients with refractory angina; however, the therapeutic efficacy in patients with ischemic cardiomyopathy is unclear. In a randomized, double-blind, placebo-controlled trial, 28 patients with advanced ischemic cardiomyopathy [New York Heart Association III-IV, LV ejection fraction (LVEF) <40 %] were assigned in 2:1 ratio to receive endomyocardial injection of BM cells (100 million, n=19) or placebo (n=9), guided by electroanatomical mapping. After 6 months, there was no significant difference between the two groups in LV ejection fraction (LVEF) and LV end-systolic volume (LVESV), LV infarct volume, and LV peri-infarct ischemic volume as determined by cardiac magnetic resonance imaging or exercise capacity. In conclusion, endomyocardial implantation of autologous BM mononuclear cells did not improve LV function or remodeling in patients with advanced ischemic cardiomyopathy. © 2014 Springer Science+Business Media.-
dc.languageeng-
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/medicine/cardiology/journal/12265-
dc.relation.ispartofJournal of Cardiovascular Translational Research-
dc.rightsThe final publication is available at Springer via http://dx.doi.org/[insert DOI]-
dc.titleEndomyocardial Implantation of Autologous Bone Marrow Mononuclear Cells in Advanced Ischemic Heart Failure: a Randomized Placebo-Controlled Trial (END-HF).-
dc.typeArticle-
dc.identifier.emailSiu, DCW: cwdsiu@hkucc.hku.hk-
dc.identifier.emailChan, WS: drwschan@hkucc.hku.hk-
dc.identifier.emailYiu, KH: khkyiu@hku.hk-
dc.identifier.emailKwong, YL: ylkwong@hku.hk-
dc.identifier.emailTse, HF: hftse@hkucc.hku.hk-
dc.identifier.authoritySiu, DCW=rp00534-
dc.identifier.authorityYiu, KH=rp01490-
dc.identifier.authorityKwong, YL=rp00358-
dc.identifier.authorityTse, HF=rp00428-
dc.identifier.doi10.1007/s12265-014-9580-6-
dc.identifier.pmid25079593-
dc.identifier.scopuseid_2-s2.0-84906790563-
dc.identifier.hkuros237968-
dc.identifier.volume7-
dc.identifier.issue6-
dc.identifier.spage545-
dc.identifier.epage552-
dc.identifier.isiWOS:000340489500001-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats